Evidence map›Paper›PMID 36388785›Full record

ArticleAnnals of translational medicine2022

Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States.

Luis E Raez, Meri Tarockoff, Carlos Rodrigo Carracedo Uribe, Jianli Niu, Candice Sareli, Nithya Sundararaman, Jayme Ion, Paula Eckardt, Andres Alvarez-Pinzon, Atif Hussein

Abstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Trends in Research on Patients With COVID-19 in Korean Medical Journals.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2024
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Luis E RaezDepartment of Hematology-Oncology, Memorial Cancer Institute/Florida International University, Pembroke Pines, FL, USA.
Meri TarockoffDepartment of Hematology-Oncology, Memorial Cancer Institute/Florida International University, Pembroke Pines, FL, USA.
Carlos Rodrigo Carracedo UribeDepartment of Internal Medicine, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Jianli NiuOffice of Human Research Memorial Health Care System, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Candice SareliOffice of Human Research Memorial Health Care System, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Nithya SundararamanOffice of Human Research Memorial Health Care System, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Jayme IonOffice of Human Research Memorial Health Care System, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Paula EckardtDivision of Infectious Diseases, Memorial Health Care System, Florida International University, Pembroke Pines, FL, USA.
Andres Alvarez-PinzonDepartment of Hematology-Oncology, Memorial Cancer Institute/Florida International University, Pembroke Pines, FL, USA.
Atif HusseinDepartment of Hematology-Oncology, Memorial Cancer Institute/Florida International University, Pembroke Pines, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To evaluate clinical outcomes in patients with malignancy who are SARS-CoV-2 (COVID-19) positive and investigate if factors such as age, gender, and race contribute to COVID-19 mortality in patients with malignancy. Methods: Retrospective data was gathered from Memorial Healthcare System of COVID-19 patients hospitalized from March 1, 2020 to January 18, 2021. Active malignancy was defined as either receiving antineoplastic therapy or being under surveillance. The primary endpoint was in-hospital mortality. Descriptive statistics were used to summarize the characteristics and outcomes. Univariate and multivariate logistic analysis were performed to define baseline clinical characteristics potentially associated with mortality in cancer patients with COVID-19. Results: A total of 4,870 COVID-19 patients were enrolled in the study, and 265 of those patients had a diagnosis of active malignancy. The study population was diverse which included non-Hispanic whites (NHW) 816 (16.8%), Hispanics 2,271 (46.6%) and Blacks 1,534 (31.5%). Of the cancer patients, 24.1% were NHW, 43% were Hispanic and 28.7% were Black. Amongst the races, 37.5% of in-hospital mortalities were NHW, while 18.4% were Hispanics and 19.7% were Black. The in-hospital mortalities amongst the two malignancy types, solid and hematological, accounted for 24.6% and 23.5% of deaths and they were not found to be statistically significant (P=0.845). After adjustments for age, gender and race were made, cancer was independently associated with an increased in-hospital mortality, with an adjusted odds ratio of 1.48 [95% confidence interval (CI): 1.08-2.01]. Increased age and elevated serum levels of creatinine and C-reactive protein (CRP) were associated with an increased risk of death in cancer patients with COVID-19. Conclusions: COVID-19 in patients with cancer had poorer outcomes in comparison to those who were cancer-free. Both hematological and solid malignancies had similar in-hospital mortality rates. The highest in-hospital mortalities of cancer patients with COVID-19 were non-Hispanic whites in-comparison to Hispanics with the least. Age, elevated levels of creatinine and CRP were independently associated with increased risk of death in cancer patients hospitalized with COVID-19. The findings indicate the need for close surveillance and monitoring of these patients as they are more likely to have higher risk of death from COVID-19.

Indexed as

anti-cancer treatmentCoronavirus-19 (COVID-19)immunotherapySARS-CoV-2

Identifiers

PMID36388785
PMCPMC9652524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.